Literature DB >> 18831712

BCL11B enhances TCR/CD28-triggered NF-kappaB activation through up-regulation of Cot kinase gene expression in T-lymphocytes.

Valeriu B Cismasiu1, Javier Duque, Elena Paskaleva, Danielle Califano, Sailaja Ghanta, Howard A Young, Dorina Avram.   

Abstract

BCL11B is a transcriptional regulator with an important role in T-cell development and leukaemogenesis. We demonstrated recently that BCL11B controls expression from the IL (interleukin)-2 promoter through direct binding to the US1 (upstream site 1). In the present study, we provide evidence that BCL11B also participates in the activation of IL-2 gene expression by enhancing NF-kappaB (nuclear factor kappaB) activity in the context of TCR (T-cell receptor)/CD28-triggered T-cell activation. Enhanced NF-kappaB activation is not a consequence of BCL11B binding to the NF-kappaB response elements or association with the NF-kappaB-DNA complexes, but rather the result of higher translocation of NF-kappaB to the nucleus caused by enhanced degradation of IkappaB (inhibitor of NF-kappaB). The enhanced IkappaB degradation in cells with increased levels of BCL11B was specific for T-cells activated through the TCR, but not for cells activated through TNFalpha (tumour necrosis factor alpha) or UV light, and was caused by increased activity of IkappaB kinase, as indicated by its increase in phosphorylation. As BCL11B is a transcription factor, we investigated whether the expression of genes upstream of IkappaB kinase in the TCR/CD28 signalling pathway was affected by increased BCL11B expression, and found that Cot (cancer Osaka thyroid oncogene) kinase mRNA levels were elevated. Cot kinase is known to promote enhanced IkappaB kinase activity, which results in the phosphorylation and degradation of IkappaB and activation of NF-kappaB. The implied involvement of Cot kinase in BCL11B-mediated NF-kappaB activation in response to TCR activation is supported by the fact that a Cot kinase dominant-negative mutant or Cot kinase siRNA (small interfering RNA) knockdown blocked BCL11B-mediated NF-kappaB activation. In support of our observations, in the present study we report that BCL11B enhances the expression of several other NF-kappaB target genes, in addition to IL-2. In addition, we provide evidence that BCL11B associates with intron 2 of the Cot kinase gene to regulate its expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18831712      PMCID: PMC2639648          DOI: 10.1042/BJ20080925

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors.

Authors:  D Avram; A Fields; K Pretty On Top; D J Nevrivy; J E Ishmael; M Leid
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

2.  COT kinase proto-oncogene expression in T cells: implication of the JNK/SAPK signal transduction pathway in COT promoter activation.

Authors:  E Sánchez-Góngora; C Lisbona; R de Gregorio; A Ballester; V Calvo; L Pérez-Jurado; S Alemany
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

Review 3.  Missing pieces in the NF-kappaB puzzle.

Authors:  Sankar Ghosh; Michael Karin
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

4.  Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappaB.

Authors:  C Tsatsanis; C Patriotis; P N Tsichlis
Journal:  Oncogene       Date:  1998-11-19       Impact factor: 9.867

5.  Nuclear factor of activated T cells and AP-1 are insufficient for IL-2 promoter activation: requirement for CD28 up-regulation of RE/AP.

Authors:  V S Shapiro; M N Mollenauer; A Weiss
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

6.  BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter.

Authors:  Valeriu B Cismasiu; Karen Adamo; Jennifer Gecewicz; Javier Duque; Qishan Lin; Dorina Avram
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

7.  The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases.

Authors:  X Lin; E T Cunningham; Y Mu; R Geleziunas; W C Greene
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

8.  Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription.

Authors:  Lawrence P Kane; Marianne N Mollenauer; Zheng Xu; Christoph W Turck; Arthur Weiss
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms.

Authors:  N Li; M Karin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 10.  NF-kappaB regulation in the immune system.

Authors:  Qiutang Li; Inder M Verma
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

View more
  21 in total

1.  Protein Kinase C-Mediated Phosphorylation of BCL11B at Serine 2 Negatively Regulates Its Interaction with NuRD Complexes during CD4+ T-Cell Activation.

Authors:  Marion Dubuissez; Ingrid Loison; Sonia Paget; Han Vorng; Saliha Ait-Yahia; Olivier Rohr; Anne Tsicopoulos; Dominique Leprince
Journal:  Mol Cell Biol       Date:  2016-06-15       Impact factor: 4.272

2.  Inhibition of tumor suppressor p53 preserves glycation-serum induced pancreatic beta-cell demise.

Authors:  Y Li; T Zhang; Q Huang; Y Sun; X Chang; H Zhang; Y Zhu; X Han
Journal:  Endocrine       Date:  2016-05-09       Impact factor: 3.633

3.  Transcription factor Bcl11b controls selection of invariant natural killer T-cells by regulating glycolipid presentation in double-positive thymocytes.

Authors:  Diana I Albu; Jeffrey VanValkenburgh; Nicole Morin; Danielle Califano; Nancy A Jenkins; Neal G Copeland; Pentao Liu; Dorina Avram
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

Review 4.  The multifaceted roles of Bcl11b in thymic and peripheral T cells: impact on immune diseases.

Authors:  Dorina Avram; Danielle Califano
Journal:  J Immunol       Date:  2014-09-01       Impact factor: 5.422

Review 5.  Mi-2/NuRD chromatin remodeling complexes regulate B and T-lymphocyte development and function.

Authors:  Carissa Dege; James Hagman
Journal:  Immunol Rev       Date:  2014-09       Impact factor: 12.988

6.  Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations.

Authors:  Saman Abbas; Mathijs A Sanders; Annelieke Zeilemaker; Wendy M C Geertsma-Kleinekoort; Jasper E Koenders; Francois G Kavelaars; Zabiollah G Abbas; Souad Mahamoud; Isabel W T Chu; Remco Hoogenboezem; Justine K Peeters; Ellen van Drunen; Janneke van Galen; H Berna Beverloo; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

7.  Short Communication: Expression of APOBEC3G and Interferon Gamma in Pleural Fluid Mononuclear Cells from HIV/TB Dual Infected Subjects.

Authors:  Zahra Toossi; Qinglai Meng; Htin Aung; Shigou Liu; Harriet Mayanja-Kizza; Christina S Hirsch
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-04       Impact factor: 2.205

Review 8.  Multilayered specification of the T-cell lineage fate.

Authors:  Ellen V Rothenberg; Jingli Zhang; Long Li
Journal:  Immunol Rev       Date:  2010-11       Impact factor: 12.988

9.  Antigen-specific clonal expansion and cytolytic effector function of CD8+ T lymphocytes depend on the transcription factor Bcl11b.

Authors:  Shuning Zhang; Mike Rozell; Raj K Verma; Diana I Albu; Danielle Califano; Jeffrey VanValkenburgh; Akeel Merchant; Javier Rangel-Moreno; Troy D Randall; Nancy A Jenkins; Neal G Copeland; Pentao Liu; Dorina Avram
Journal:  J Exp Med       Date:  2010-07-26       Impact factor: 14.307

10.  Increased expression of bcl11b leads to chemoresistance accompanied by G1 accumulation.

Authors:  Piotr Grabarczyk; Viola Nähse; Martin Delin; Grzegorz Przybylski; Maren Depke; Petra Hildebrandt; Uwe Völker; Christian A Schmidt
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.